Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

I.V. Busulfan Given Based on Body Weight in Combination with Cyclophosphamide in Children: Pharmacokinetic and Clinical Results of a Myeloablative, Reduced-Toxicity Conditioning Regimen for Allogeneic Stem Cell Transplantation.

Helene Esperou, MD, Bénédicte Neven, MD, Karima Yakouben, MD, Claire Galambrun, MD, Françoise Méchinaud, MD, Catherine Paillard, MD, Pierre Bordigoni, MD, Hamadi Zouabi, MD, Laurent Nguyen, PharD, Gérard Michel, MD, Gilles Vassal, MD PhD

Blood (2006) 108 (11): 5131.

https://doi.org/10.1182/blood.V108.11.5131.5131

Published: 2006

Journal Articles

A New IV Busulfan Fixed Dosing as Part of BuMel or BuCy Conditioning Regimens: A Pharmacokinetic/Pharmacodynamic Study in Pediatric Patients Undergoing Autologous or Allogeneic Hematopoietic Stem Cell Transplantation.

Gilles Vassal, MD, PhD, Hélène Esperou, MD, Dominique Valteau-Couanet, MD, Jean Claude Gentet, MD, François Doz, MD, Françoise Méchinaud, MD, Claire Galambrun, MD, Alain Fischer, MD, Hamadi Zouabi, MD, Laurent Nguyen, Pharm D, Gérard Michel, MD

Blood (2005) 106 (11): 5200.

https://doi.org/10.1182/blood.V106.11.5200.5200

Published: 2005

Journal Articles

A New Busulfan Fixed Dosing for Conditioning before Autologous or Allogeneic Hematopoietic Stem Cell Transplantation in Children with Malignant and Non-Malignant Diseases: Pharmacokinetics, Toxicity and Clinical Outcomes.

Gérard Michel, MD, Dominique Valteau-Couanet, MD, Hélène Esperou, MD, Jean Claude Gentet, MD, François Doz, MD, Françoise Méchinaud, MD, Claire Galambrun, MD, Alain Fischer, MD, Hamadi Zouabi, MD, Christian Puozzo, PhD, Gilles Vassal, MD, PhD

Blood (2005) 106 (11): 1758.

https://doi.org/10.1182/blood.V106.11.1758.1758

Published: 2005

Journal Articles

Is CDKN2A +/− CDKN2B and MTAP Inactivation of Prognostic Significance in B-Precursor Childhood Acute Lymphoblastic Leukemia? Results of EORTC Studies 58881 and 58951.

Delphine Mirebeau, MD, Cécile Acquaviva, PharmD, Stefan Suciu, PHD, Raphaëlle Bertin, PharmD, Alain Robert, MD, Patrick Boutard, MD, Françoise Méchinaud, MD, Emmanuel Plouvier, MD, Jacques Otten, MD, Etienne Vilmer, MD, Hélène Cavé, PharmD, PHD

Blood (2004) 104 (11): 1076.

https://doi.org/10.1182/blood.V104.11.1076.1076

Published: 2004

Journal Articles

Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951

Blood (2004) 103 (2): 442–450.

https://doi.org/10.1182/blood-2003-05-1495

Published: 2004

NARROW

I.V. Busulfan Given Based on Body Weight in Combination with Cyclophosphamide in Children: Pharmacokinetic and Clinical Results of a Myeloablative, Reduced-Toxicity Conditioning Regimen for Allogeneic Stem Cell Transplantation.

A New IV Busulfan Fixed Dosing as Part of BuMel or BuCy Conditioning Regimens: A Pharmacokinetic/Pharmacodynamic Study in Pediatric Patients Undergoing Autologous or Allogeneic Hematopoietic Stem Cell Transplantation.

A New Busulfan Fixed Dosing for Conditioning before Autologous or Allogeneic Hematopoietic Stem Cell Transplantation in Children with Malignant and Non-Malignant Diseases: Pharmacokinetics, Toxicity and Clinical Outcomes.

Is CDKN2A +/− CDKN2B and MTAP Inactivation of Prognostic Significance in B-Precursor Childhood Acute Lymphoblastic Leukemia? Results of EORTC Studies 58881 and 58951.

Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951

Email alerts

ASH Publications

American Society of Hematology

I.V. Busulfan Given Based on Body Weight in Combination with Cyclophosphamide in Children: Pharmacokinetic and Clinical Results of a Myeloablative, Reduced-Toxicity Conditioning Regimen for Allogeneic Stem Cell Transplantation.

A New IV Busulfan Fixed Dosing as Part of BuMel or BuCy Conditioning Regimens: A Pharmacokinetic/Pharmacodynamic Study in Pediatric Patients Undergoing Autologous or Allogeneic Hematopoietic Stem Cell Transplantation.

A New Busulfan Fixed Dosing for Conditioning before Autologous or Allogeneic Hematopoietic Stem Cell Transplantation in Children with Malignant and Non-Malignant Diseases: Pharmacokinetics, Toxicity and Clinical Outcomes.

Is CDKN2A +/− CDKN2B and MTAP Inactivation of Prognostic Significance in B-Precursor Childhood Acute Lymphoblastic Leukemia? Results of EORTC Studies 58881 and 58951.

Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only